All News

Efforts include a mandatory intravenous immunoglobulin ordering form, blood bank gatekeeping, and a stewardship committee to ensure optimized use.

Lerodalcibep is a novel, third-generation, anti-PCSK9 therapy small binding protein.

Pharmacists, who play a crucial role at the intersection of prescribing and dispensing, are well-positioned to influence these disparities.

In addition to GLP-1s, dual GLP-1 and GIP agonists, intestinal lipase inhibitors, sympathomimetics, and other agents can help patients lose weight.

Expanding operations to provide specialty infusions can provide benefits to both patients and oncology practices.

Among this population, about 80% had not previously been diagnosed with asthma and over 30% were not using any asthma medications.

Opioid stewardship pharmacist Maureen Saphire, PharmD, BCGP, focuses on advocating for appropriate opioid access for patients with cancer and sickle cell disease, promoting safe opioid use, and supporting leadership and strategic planning as keys to successful opioid stewardship.

New technology and innovation may help turn the corner on antibiotic resistance.

Brian Anderson, PharmD, RPh provides important considerations for pharmacists regarding patient use of benzodiazepines.

Increased bone marrow adiposity is associated with progression of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma.

Known to be a leading cause of mortality worldwide, cigarette smoke exposure can make the respiratory tract more susceptible to pneumococcal infection.

RBL is the first FDA-approved microbiota-based live biotherapeutic product for adults.

For up to 6 years, cognitive remediation and transcranial direct current stimulation slowed cognitive decline associated with major depressive disorder in remission and mild cognitive impairment.

The authors believe that improvements can be made to overlook the motherhood penalty and its associated pay gaps as well as changes to address workforce burnout.

Trent Thiede, PharmD, president of Pharmacy Audit Assistance Service (PAAS) International, discussed how pharmacy teams can remain prepared for audits from pharmacy benefit managers (PBMs).

Patients with low-grade intermediate-risk non-muscle-invasive bladder cancer who achieved a complete response rate after 3 months of UGN-102 treatment had an 82.3% duration of response at 12 months.

Insomnia exhibits a dose-response relationship with AF recurrence, indicating that an increased number of insomnia symptoms is associated with heightened probability of AF recurrence.

The 2024 American Association of Colleges of Pharmacy Annual Meeting took place from July 20 to July 23, 2024, in Boston, Massachusetts.

Educating the public about the dangers of self-medication and the importance of finishing prescribed antibiotic courses plays a crucial role

Jeff Boyer, PharmD, BCPS, discusses his role in opioid stewardship at the Southern Arizona VA Healthcare System, highlighting his work in pain management coordination, interdisciplinary collaboration, patient and provider education, and data-driven strategies to support safe opioid use and address the opioid crisis.

The findings show robust connections between symptoms, with variations in depression scores directly or indirectly influence fatigue and other symptoms.

Kristi Veis discusses the importance of flu vaccinations and the role of pharmacists in administering them.

Less than 16% of high-risk lung cancer individuals have heard or discussed lung cancer screenings with a health care provider.

The results found that women, non-binary, and sexual minority students are at the highest risk.

Using in vitro models, study investigators predict the risk of bone metastasis in breast cancer based on correlations with their in vivo behaviors and potential.

Erin Rexroth, associate director of marketing for NCPA, discussed how pharmacies can utilize marketing strategies to drive awareness and patient engagement.

The novel therapy demonstrated safety and efficacy in a clinical trial.

About 41% and 30% of patients with chronic spontaneous urticaria (CSU), respectively, achieved well-controlled disease status and complete response when treated with dupilumab.